The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index; 108 of the 144 sources its claims cite were checked for support.
Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review
Open accessAbstract
Adherence and Adherence/Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review. Global persistence varies widely: from approximately 75–80% at 12 months in reimbursed T2DM cohorts to below 10% in obesity-focused or high out-of-pocket-cost settings; in several cohorts, persistence falls below 15% by 24 months. The primary drivers are gastrointestinal intolerance and economic barriers.
Overview
CoChat Summary
TL;DR
This narrative review synthesizes international real-world evidence showing that GLP-1 receptor agonist persistence is highly variable and substantially below clinical-trial retention, driven mainly by gastrointestinal intolerance and economic barriers. It proposes integrating medical nutrition therapy and structured lifestyle/behavioral support into routine GLP-1 care, while acknowledging that most supporting evidence is extrapolated rather than derived from GLP-1-specific randomized trials.
Key findings
- Real-world persistence ranged from approximately 75–80% at 12 months in reimbursed T2DM cohorts (Sweden ~76.4%; Denmark ~78.8%) to below 10% in obesity-focused or high out-of-pocket settings (Poland 6.6% long-term persistence; Colombia 0.2% at 12 months); U.S. company-published data reported 8.1% persistence at 3 years, and UK data reported ~54.8% at 12 months and ~35.3% at 24 months.
- GI intolerance and economic barriers were the primary drivers; in STEP UP, GI adverse events occurred in ~71% with semaglutide 7.2 mg vs 61% with 2.4 mg and 43% with placebo, and a cross-sectional survey found patients most often cited nausea (64.4%) and vomiting (45.4%), while physicians most often cited inadequate glycemic control (45.6%) and nausea/vomiting (43.8%).
- The proposed nutritional framework includes protein targets of 1.2–1.5 g/kg/day in chronic illness and up to ~1.6 g/kg/day during active weight loss, resistance training 2–3 times weekly, nutrient-dense lower-volume meals, and micronutrient screening; U.S. Medicare MNT coverage excludes obesity without T2DM or CKD.
- Cardiovascular benefit may be partly independent of weight loss: SELECT showed a 20% MACE reduction, and a prespecified analysis suggested waist-circumference reduction mediated only approximately one-third of the treatment effect.
Methods
- Narrative review using PubMed as the primary database, supplemented by Embase, Google Scholar, and hand-searching; English-language publications from inception through 31 January 2026 in adults ≥19 years. The primary PubMed search identified 5523 records, reduced to 3935 human studies and 2138 adult studies, with 87 publications included in the final synthesis.
- Eligible sources included RCTs, prospective/retrospective cohorts, insurance claims and pharmacy benefit analyses, national registry studies, systematic reviews/meta-analyses, and consensus documents; exclusions included non-English publications, pediatric-only studies, single case reports unless illustrating a novel mechanistic concept, and non-peer-reviewed grey literature except labeled company-reported real-world evidence.
- No formal risk-of-bias assessment, GRADE rating, or meta-analytic synthesis was performed; studies were selected by topical relevance, prioritizing landmark RCTs, large real-world cohort/claims analyses, and recent 2023–2026 primary publications.
Limitations
- Stated: as a narrative rather than systematic review, selection and synthesis are subject to selection bias; no formal risk-of-bias assessment, GRADE rating, or meta-analysis was performed. Persistence definitions, allowable gap thresholds (60 vs 90 days), follow-up durations, and data sources differ across studies, precluding direct quantitative cross-cohort comparison, and the evidence base is predominantly from high-income settings, limiting generalizability to low- and middle-income countries.
- Stated: many nutritional and behavioral recommendations are extrapolated from related populations or expert consensus rather than GLP-1-specific randomized trials; direct randomized evidence for integrated MNT/behavioral support improving persistence is limited. The microbiota evidence comes from a single 60-day RCT in 25 adults, the neuroimaging evidence is a single-patient case, and the dietary volume/gastric-stasis mechanism has not been tested in randomized dietary-modification trials within GLP-1 RA cohorts.
- Evident: the review includes company-published, non-peer-reviewed real-world data (e.g., Prime Therapeutics, Omada Health), and the Omada cohort was self-selected, digitally engaged, and commercially insured; the AI-driven lifestyle RCT was conducted in a non-GLP-1-using population, and several cited sources are cross-sectional surveys or single-case observations, limiting causal inference.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
65 Valid · 8 Not valid · 25 Not checked · 49 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When a patient receiving a high-dose GLP-1 RA consumes a high-fat meal, the combined effect of pharmacological and endogenous lipid-mediated signaling can produce profound gastric stasis [27,33].”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 3. Physiology of GLP-1 and Nutritional Interaction > 3.2. Nutritional Feedback Loops and Adverse Events
What the sources say
- Partly supportedcites [27] Mozaffarian, 2025, Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society, Am. J. Lifestyle Med. sourceExperimental — accuracy not yet measured
The Side effects section says GLP-1 therapy delays gastric emptying and that higher doses are more likely to cause GI symptoms. The Management of GI side effects section says fatty foods can further slow gastric emptying, while Dietary modulation of GLP-1 release and action says certain fatty acids stimulate endogenous GLP-1 release. The paper does not establish that these effects combine in a high-dose patient after a high-fat meal to produce profound gastric stasis. Page numbers were not available in our copy. (LLM, conf=0.87)
- Partly supportedcites [33] Gentinetta, 2024, Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist, Diabetes Metab. Syndr. Obes. sourceExperimental — accuracy not yet measured
The GLP-1 Receptor Agonists and Their Adverse Events section says GLP-1RAs delay gastric emptying and that fatty acids can increase endogenous GLP-1 levels. The Results > Fats section says fats may also delay gastric emptying. Neither section establishes that a high-fat meal combined with a high-dose GLP-1RA produces profound gastric stasis, or attributes that outcome to combined signaling. Page numbers are unavailable in our copy. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Yet the dominant physiological driver of discontinuation and non-persistence remains gastrointestinal (GI) intolerance, an intrinsic consequence of GLP-1 receptor activation in the gut and brainstem [23,24].”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 1. Introduction
What the sources say
- Partly supportedcites [23] Aldhaleei, W.A., Abegaz, T.M., and Bhagavathula, A.S. (2024). Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort. Pharmaceuticals, 17. sourceExperimental — accuracy not yet measured
The Results (§2.3; page not provided) report frequent gastrointestinal adverse events among GLP-1 RA users, and the Discussion (§3) describes differences in GI tolerability between agents. The paper does not establish that GI intolerance is the dominant driver of discontinuation or non-persistence, or attribute it to receptor activation in the gut and brainstem. (LLM, conf=0.86)
- Partly supportedcites [24] Ismaiel, 2025, Gastrointestinal Adverse Events Associated with GLP-1 RA in Non-Diabetic Patients with Overweight or Obesity: A Systematic Review and Network Meta-Analysis, Int. J. Obes. sourceExperimental — accuracy not yet measured
The Discussion (page not provided) says persistent gastrointestinal symptoms can lead to treatment discontinuation and affect adherence. It does not establish GI intolerance as the dominant driver of discontinuation or non-persistence. The Introduction (page not provided) says the mechanism remains incompletely understood and discusses gastrointestinal motility and secretion, not a demonstrated gut-and-brainstem mechanism. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“whether lean-mass loss itself directly precipitates early treatment discontinuation, however, has not been established [25,26].”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 1. Introduction
What the sources say
- Could not verifycites [25] Jensen, 2024, Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial, JAMA Netw. Open sourceExperimental — accuracy not yet measured
The Results sections on Body Weight and Body Composition and Compliance report lean-mass changes and medication discontinuations separately, without examining whether one caused the other. Our copy does not state whether a direct link between lean-mass loss and early treatment discontinuation has been established; searches for that link and for discontinuation did not find one. The indexed passages provide no page numbers. (LLM, conf=0.72)
- Could not verifycites [26] Sato, 2025, Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions, J. Cachexia Sarcopenia Muscle sourceExperimental — accuracy not yet measured
The ‘Weight Regain After Intervention Withdrawal’ section reports that fewer than half of patients remain on these medications after one year, while the ‘Incretins and Muscle Loss’ section discusses lean-tissue loss. Neither section addresses whether lean-mass loss causes early discontinuation or explicitly says that this relationship has not been established. Searched for reasons for withdrawal, adherence, and discontinuation due to muscle or lean-mass loss; page numbers were not available in our copy. (LLM, conf=0.70)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“A dose–response relationship exists between cost-sharing and adherence: patients in the highest out-of-pocket cost quartiles have significantly greater odds of nonadherence [57].”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 5. Barriers to Adherence and Persistence with GLP-1 Therapy > 5.2. Economic and Structural Barriers
What the sources say
- Supportedcites [57] Zhang, 2025, Association of Patient Cost Sharing With Adherence to GLP-1RA and Adverse Health Outcomes, Diabetes Care source
The Results report a significant monotonic relationship between out-of-pocket costs and proportion of days covered. Table 2 also shows significantly higher odds of GLP-1RA nonadherence in the highest cost quartile than in the lowest (OR 1.25, 95% CI 1.19–1.31) among adults with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“This coverage gap creates a paradox in which patients receive highly potent pharmacotherapies without financial access to the nutritional expertise required to use them safely and effectively [65].”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 6. Nutritional Support Strategies > 6.1. The Academy of Nutrition and Dietetics Position Statement and Pharmacoeconomic Implications
What the sources say
- Partly supportedcites [65] Rowland, 2025, Expansion of Medicare Coverage for Medical Nutrition Therapy, JAMA Netw. Open sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says Medicare covers dietitian-provided medical nutrition therapy only for specified conditions, and the Results (page unavailable) show that proposed expansion would increase eligibility from 30.3% to 85.1% of beneficiaries. This supports a coverage gap, but the paper does not say patients receive potent pharmacotherapies or that nutritional expertise is required to use those drugs safely and effectively. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
56 more claims · 26 with their cited sources checked
Create a free account to see all 147 claims and to verify the 5 references still open.
- It may state two separate claims as one. 74
- Probably not a substantial claim. 21
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 5. Barriers to Adherence and Persistence with GLP-1 Therapy > 5.2. Economic and Structural Barriers
“persistence fell from 35.4% at one month to 13.8% at six months and 0.2% at twelve months”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 4. Global Epidemiology of Adherence and Persistence > 4.4. Latin America
“35.4% abandoned treatment after a single month”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 6. Nutritional Support Strategies > 6.1. The Academy of Nutrition and Dietetics Position Statement and Pharmacoeconomic Implications
“In a position paper published in late 2025, the Academy of Nutrition and Dietetics stated that all individuals receiving obesity pharmacotherapy should have concurrent access to evidence-based MNT delivered by a registered dietitian nutritionist (RDN) [27].”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > References
“27. Mozaffarian D. Agarwal M. Aggarwal M. Alexander L. Apovian C.M. Bindlish S. Bonnet J. Butsch W.S. Christensen S. Gianos E. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > 2. Methods > 2.3. Inclusion and Exclusion Criteria
“Exclusion criteria comprised non-English-language publications, studies conducted exclusively in pediatric populations, single case reports unless illustrating a novel mechanistic concept (e.g., the neuroimaging case study cited in Section 5.3), and non-peer-reviewed grey literature, except where explicitly labeled as company-reported real-world evidence.”
§ Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review > References
“60. Dang V. Sambuco N. Yammine L. Versace F. Do GLP-1 Receptor Agonists Alter Brain Responses to Reward-Related Cues? A Systematic Review bioRxiv 2026 10.64898/2026.01.31.702984”
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 3×
“The most successful weight-loss trials to date—including the STEP program for semaglutide [9] and the SURMOUNT program for tirzepatide [13]—have incorporated intensive lifestyle interventions as a core component of the trial protocol, modeled on the structured behavioral curricula pioneered by the…”
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 3×
“Furthermore, landmark trials such as SELECT have confirmed significant reductions in major adverse cardiovascular events (MACE), establishing these agents as systemic disease-modifying therapies beyond glycemic and weight control [7,14,15].”
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020 · cited 1×
“…date—including the STEP program for semaglutide [9] and the SURMOUNT program for tirzepatide [13]—have incorporated intensive lifestyle interventions as a core component of the trial protocol, modeled on the structured behavioral curricula pioneered by the Diabetes Prevention Program (DPP) [76,77].”
Bauer, J., Biolo, G., Cederholm, T., Cesari, M., Cruz-Jentoft, A. J., Morley, J. E., Phillips, S., Sieber, C., Stehle, P., Teta, D., et al. (2013) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2013.05.021 · Cited by 2,553
How are habits formed: modelling habit formation in the real world
Lally, P., van Jaarsveld, C. H. M., Potts, H. W. W., & Wardle, J. (2010) · European Journal of Social Psychology · doi:10.1002/ejsp.674 · Cited by 2,036 · cited 1×
“While nutritional strategies address the physiological side effects of GLP-1 RAs, behavioral interventions target the psychological barriers and habit-formation processes critical for long-term persistence [80–82].”
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Deutz, N. E. P., Bauer, J. M., Barazzoni, R., Biolo, G., Boirie, Y., Bosy-Westphal, A., Cederholm, T., Cruz-Jentoft, A., Krznariç, Z., Nair, K. S., et al. (2014) · Clinical Nutrition · doi:10.1016/j.clnu.2014.04.007 · Cited by 1,738 · cited 1×
“…position paper, synthesizing nitrogen-balance and clinical-outcome studies, recommends a minimum daily intake of 1.0–1.2 g/kg/day for healthy older adults and 1.2–1.5 g/kg/day for those with acute or chronic illness [68]; corresponding ESPEN consensus recommendations align closely [69].”
InfluentialRosenstock, J., Wysham, C., Frías, J. P., Kaneko, S., Lee, C. J., Fernández Landó, L., Mao, H., Cui, X., Karanikas, C. A., & Thieu, V. T. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01324-6 · Cited by 1,080 · cited 1×
“Foundational studies such as STEP [9,10] and SURPASS [11,12] established high benchmarks for weight reduction, while recent data from the SURMOUNT-5 [13] head-to-head trial demonstrated that dual agonism with tirzepatide can achieve mean body weight reductions exceeding 20%.”
Lifestyle modification approaches for the treatment of obesity in adults.
Wadden, T. A., Tronieri, J. S., & Butryn, M. L. (2020) · American Psychologist · doi:10.1037/amp0000517 · Cited by 661
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416394 · Cited by 634 · cited 2×
“The most successful weight-loss trials to date—including the STEP program for semaglutide [9] and the SURMOUNT program for tirzepatide [13]—have incorporated intensive lifestyle interventions as a core component of the trial protocol, modeled on the structured behavioral curricula pioneered by the…”
Research works printed but not linked: 1
- (2005). Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate, National Academies Press.
Cited by
Dziewierz, A., Kulicka, N., Łupina, K., Maruszak, N., Gałuszka, A., Domienik‐Karłowicz, J., Rulkiewicz, A., & Siudak, Z. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113493
Self-citationKamrul-Hasan, A. B. M., Ashraf, H., Nagendra, L., Khalil, I., Chatterjee, S., Dutta, D., Haq, T., Alanazi, M. A., & Pappachan, J. M. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70181 · Cited by 1
Metadata
- Authors
- Dziewierz, A., & Siudak, Z.
- Affiliations
- Jagiellonian University (PL)
- Jan Kochanowski University (PL)
- Corresponding author
- Siudak, Zbigniew
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2026-05-30
- Volume
- 18
- Issue
- 11
- Pages
- 1761
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC13259006
- OpenAlex
- W7163024474
- Cited by
- 3
- References
- 74
- Citations by year
- 2026: 3
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Keywords
- GLP-1 receptor agonists, treatment persistence, medication adherence, type 2 diabetes, obesity, medical nutrition therapy, gastrointestinal intolerance, protein intake, lean mass loss, gastric emptying, cost barriers, integrated care, real-world effectiveness
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adherence Interventions, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Life Style, Obesity, Weight Loss, Nutrition Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review. https://app.cochat.ai/papers/10.3390/nu18111761
- The paper
- Dziewierz, A., & Siudak, Z. (2026). Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review. Nutrients. https://doi.org/10.3390/nu18111761
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.